Preliminary Study on the Expression and the Clinical Significance of CD133 in Peripheral Blood of Patients with Gastric Adenocarcinoma

Table 4

Multivariate risk analysis on the correlation of the BSV of postoperative CD133 mRNA in PBMCs with clinicopathological features.

Parameters	𝐵	S.E.	Wald	df	Sig.	Exp(𝐵)	95.0% of CI
							Lower	Upper
Gender	0.056	0.870	0.004	1	0.948	1.058	0.192	5.817
Size of tumor	−1.309	0.955	1.877	1	0.171	0.270	0.042	1.757
Lauren type	0.794	1.368	0.338	1	0.561	2.212	0.152	32.196
Histological type	1.780	1.230	3.812	2	0.149	0.332	0.010	2.322
Vascular invasion	−0.525	1.104	0.226	1	0.634	0.592	0.068	5.151
Lymphatic vessel invasion	3.487	1.133	3.899	1	0.033	0.096	0.011	0.831
Invasive depth	5.149	1.227	3.069	1	0.018	8.580	0.775	95.016
Lymph node metastasis	0.917	1.605	0.327	1	0.568	2.502	0.108	58.140
TNM stage	2.680	2.035	1.734	1	0.188	14.587	0.270	787.336
CD133 mRNA in primary tissue	4.842	2.885	2.818	1	0.093	0.008	0.000	2.251
CD133 protein expressed in primary tissue	0.951	1.021	0.867	1	0.352	2.588	0.350	19.159
MLR	−0.084	0.054	2.411	1	0.121	0.919	0.826	1.022
Metastatic lymph node number	0.445	0.264	2.847	1	0.092	1.562	0.931	2.619
Dissected lymph node number	−0.134	0.078	2.987	1	0.084	0.875	0.751	1.018